Table 1

Treatment	Incidence of EAE	Mean peak clinical score	Alteration of EAE
Treatment	Incidence of EAE	Mean peak clinical score	Incidence	Score
MBP-primed T cells	6/6	3.0
PTIO-treated MBP-primed T cells	5/6	1.66	- 17%	- 45% ^a
DETA-NONOate-treated MBP-primed T cells	6/6	3.66		+ 22% ^b

LNC isolated from MBP-immunized donor female SJL/J mice were re-primed with MBP in the presence of either PTIO (50 μM), or DETA-NONOate (100 μM). After 4 days, viable non-adherent cells (2 x 10⁷) were adoptively transferred to naïve female SJL/J recipient mice via tail-vein injection. A clinical score of 1 or more was considered as the incidence of EAE in mice. ^ap < 0.001 &^bp < 0.05 vs MBP-primed T cells (control).

Table 1: Effect of DETA-NONOate and PTIO on encephalitogenicity of female MBP-primed T cells.